Reduced Efficacy for CRC Screenings Done by Non-GI Docs

This article originally appeared here.
Share this content:
Reduced Efficacy for CRC Screenings Done by Non-GI Docs
Reduced Efficacy for CRC Screenings Done by Non-GI Docs

(HealthDay News) – Having interval colorectal cancer (CRC) colonoscopy screenings performed by nongastroenterologists compared with gastroenterologists (GIs) results in a noticeable reduction in the long-term CRC prevention rate, according to research published online June 15 in Cancer.

Cesare Hassan, MD, of the Nuovo Regina Margherita Hospital in Rome, and colleagues created a Markov model to simulate the efficacy and cost of a colonoscopy population of 100,000 people screened, beginning at age 50. Based on the literature, the researchers used a relative risk of 1.4 for the difference between GI endoscopists and non-GI endoscopists.

Using this model, the researchers found that the use of non-GI endoscopists to perform interval colonoscopies resulted in an 11% relative reduction in the long-term CRC incidence prevention rate. In the United States, this would result in an additional 3,043 cases of CRC and would cost an additional $200 million annually. Increasing the relative risk to 2.0 and 3.0 led to 19 and 38% relative reductions, respectively, in CRC prevention. In order to shift all colonoscopies to gastroenterologists, it would require each endoscopist to perform an additional 165 screenings per year.

"When screening colonoscopy is performed by non-GI endoscopists, a substantial reduction in the long-term CRC prevention rate may be expected," the authors write. "Such difference appeared to be greater when a suboptimal efficacy of colonoscopy in preventing CRC was assumed. A ten-year saving of $2 billion may be expected when shifting all screening colonoscopies from non-GI endoscopists to GI endoscopists."

One author disclosed receiving research support from Olympus.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs